Influence of inhibitors of the renin–angiotensin system on risk of acute respiratory distress syndrome in Danish hospitalized COVID-19 patients
Anders Holt, Ikram Mizrak, Morten Lamberts, Per Lav Madsen
Journal of Hypertension, doi:10.1097/hjh.0000000000002515
OVID-19, the disease associated with SARS-CoV-2 infection, is in some 20% of acutely affected patients associated with respiratory distress syndrome (ARDS) often necessitating respirator treatment and associated with a high mortality [1] [2] [3] . Epidemics in Wuhan in China and Lombardy in Italy have been devastating, and SARS-CoV-2 has developed into a pandemic necessitating urgent worldwide co-operation. Until effective treatment of COVID-19 including a useful vaccination against SARS-CoV-2 is found, it is important to seek ways of limiting or avoiding ARDS. Virus-related ARDS is initiated from a high level of angiotensin II (Ang-II) via the type 1 receptor pathway [4], and Ang-II has already been demonstrated to be high in COVID-19 and linearly associated with lung injury [5] . Inhibitors of the renin-angiotensin system (RASi), cornerstones of treatment of patients with hypertension and heart failure, have attracted attention as they may in theory influence the Ang-II level in COVID-19 and thereby the risk of ARDS [4, 6] . In short, Ang-II activity is influenced by the balance of Ang-converting enzyme (ACE) and ACE2 receptor activity. The activity of ACE2 normally lowers the level of Ang-II, but SARS-CoV-2 virus binds to ACE2 receptors, lower their activity and hence increase Ang-II activity [1] . While RASi lower Ang-II levels, and may in this respect be helpful, chronic RASi treatment may on the other hand also increase pulmonary ACE2-receptor numbers hence providing a possible higher SARS-CoV-2 viral load. As suggested from animal experiments, chronic treatment with RASi can therefore, in theory, both increase and lower the risk of ARDS in SARS-CoV-2-infected patients. Studies early listed heart disease, hypertension, and diabetes as risk factors for ARDS [1-3], but unfortunately medication has not yet been reported on, and clinical data on the relative importance of RASi for outcome in COVID-19 are now urgently needed. Approved by the Danish Patient Safety Authority and the Danish Data Protection Agency, we related medication to outcome in all SARS-CoV-2 PCR positive patients, who,
References
Esler, Esler, Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?, J Hypertens
Grasselli, Zangrillo, Zanella, Antonelli, Cabrini et al., Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy, JAMA
Liu, Yang, Zhang, Huang, Wang et al., Clinical and biochemical indexes from 2019-nCOV infected patients linked to viral loads and lung injury, Sci China Life Sci
Vaduganathan, Vardeny, Michel, Mcmurray, Pfeffer et al., Renin-angiotensin-aldosterone system inhibitors in patients with COVID-19, N Engl J Med
Yang, Zheng, Gou, Pu, Chen et al., Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis, Int J Infect Dis
Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet
{ 'indexed': {'date-parts': [[2022, 9, 1]], 'date-time': '2022-09-01T08:34:51Z', 'timestamp': 1662021291935},
'reference-count': 6,
'publisher': 'Ovid Technologies (Wolters Kluwer Health)',
'issue': '8',
'content-domain': {'domain': [], 'crossmark-restriction': False},
'published-print': {'date-parts': [[2020, 8]]},
'DOI': '10.1097/hjh.0000000000002515',
'type': 'journal-article',
'created': {'date-parts': [[2020, 5, 8]], 'date-time': '2020-05-08T20:50:27Z', 'timestamp': 1588971027000},
'page': '1612-1613',
'source': 'Crossref',
'is-referenced-by-count': 7,
'title': 'Influence of inhibitors of the renin–angiotensin system on risk of acute respiratory distress '
'syndrome in Danish hospitalized COVID-19 patients',
'prefix': '10.1097',
'volume': '38',
'author': [ {'given': 'Anders', 'family': 'Holt', 'sequence': 'first', 'affiliation': []},
{'given': 'Ikram', 'family': 'Mizrak', 'sequence': 'additional', 'affiliation': []},
{'given': 'Morten', 'family': 'Lamberts', 'sequence': 'additional', 'affiliation': []},
{'given': 'Per', 'family': 'Lav Madsen', 'sequence': 'additional', 'affiliation': []}],
'member': '276',
'published-online': {'date-parts': [[2020, 5, 7]]},
'reference': [ { 'key': 'R1-20210211',
'doi-asserted-by': 'crossref',
'first-page': '1574',
'DOI': '10.1001/jama.2020.5394',
'article-title': 'Baseline characteristics and outcomes of 1591 patients infected with '
'SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy',
'volume': '323',
'author': 'Grasselli',
'year': '2020',
'journal-title': 'JAMA'},
{ 'key': 'R2-20210211',
'doi-asserted-by': 'crossref',
'first-page': '1054',
'DOI': '10.1016/S0140-6736(20)30566-3',
'article-title': 'Clinical course and risk factors for mortality of adult inpatients with '
'COVID-19 in Wuhan, China: a retrospective cohort study',
'volume': '395',
'author': 'Zhou',
'year': '2020',
'journal-title': 'Lancet'},
{ 'key': 'R3-20210211',
'doi-asserted-by': 'crossref',
'first-page': '91',
'DOI': '10.1016/j.ijid.2020.03.017',
'article-title': 'Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) '
'infection: a systematic review and meta-analysis',
'volume': '94',
'author': 'Yang',
'year': '2020',
'journal-title': 'Int J Infect Dis'},
{ 'key': 'R4-20210211',
'doi-asserted-by': 'crossref',
'first-page': '1653',
'DOI': '10.1056/NEJMsr2005760',
'article-title': 'Renin–angiotensin–aldosterone system inhibitors in patients with '
'COVID-19',
'volume': '382',
'author': 'Vaduganathan',
'year': '2020',
'journal-title': 'N Engl J Med'},
{ 'key': 'R5-20210211',
'doi-asserted-by': 'crossref',
'first-page': '364',
'DOI': '10.1007/s11427-020-1643-8',
'article-title': 'Clinical and biochemical indexes from 2019-nCOV infected patients '
'linked to viral loads and lung injury',
'volume': '63',
'author': 'Liu',
'year': '2020',
'journal-title': 'Sci China Life Sci'},
{ 'key': 'R6-20210211',
'doi-asserted-by': 'crossref',
'first-page': '781',
'DOI': '10.1097/HJH.0000000000002450',
'article-title': 'Can angiotensin receptor-blocking drugs perhaps be harmful in the '
'COVID-19 pandemic?',
'volume': '38',
'author': 'Esler',
'year': '2020',
'journal-title': 'J Hypertens'}],
'container-title': 'Journal of Hypertension',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://journals.lww.com/10.1097/HJH.0000000000002515',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2021, 2, 24]],
'date-time': '2021-02-24T10:32:13Z',
'timestamp': 1614162733000},
'score': 1,
'resource': {'primary': {'URL': 'https://journals.lww.com/10.1097/HJH.0000000000002515'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2020, 5, 7]]},
'references-count': 6,
'journal-issue': {'issue': '8', 'published-print': {'date-parts': [[2020]]}},
'URL': 'http://dx.doi.org/10.1097/hjh.0000000000002515',
'relation': {},
'ISSN': ['0263-6352', '1473-5598'],
'subject': ['Cardiology and Cardiovascular Medicine', 'Physiology', 'Internal Medicine'],
'published': {'date-parts': [[2020, 5, 7]]}}
